Blood Test for Multiple Cancers: Many False Positives

"As this technology develops, people must continue with their standard cancer screening, but this is a glimpse of what the future may hold," commented study investigator Deborah Schrag, MD, MPH, chair, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City.

For the PATHFINDER study, the Galleri blood test (developed by Grail) was used in 6621 healthy individuals aged over 50, with or without additional cancer risk factors (such as history of smoking or genetic risk).